WO2000068259A3 - Vaccine - Google Patents

Vaccine Download PDF

Info

Publication number
WO2000068259A3
WO2000068259A3 PCT/IB2000/000726 IB0000726W WO0068259A3 WO 2000068259 A3 WO2000068259 A3 WO 2000068259A3 IB 0000726 W IB0000726 W IB 0000726W WO 0068259 A3 WO0068259 A3 WO 0068259A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyogenes
streptococcus
group
polypeptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2000/000726
Other languages
French (fr)
Other versions
WO2000068259A2 (en
Inventor
Gunnar Lindahl
Margareth Stalhammar-Carlemalm
Thomas Areschoug
Charlotte Larsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STALHAMMAR CARLEMALM MARGARETH
Original Assignee
STALHAMMAR CARLEMALM MARGARETH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STALHAMMAR CARLEMALM MARGARETH filed Critical STALHAMMAR CARLEMALM MARGARETH
Priority to DE60022995T priority Critical patent/DE60022995T2/en
Priority to CA002372497A priority patent/CA2372497A1/en
Priority to EP00927666A priority patent/EP1175437B1/en
Priority to AT00927666T priority patent/ATE305941T1/en
Priority to AU46051/00A priority patent/AU778526B2/en
Priority to US09/959,594 priority patent/US7220415B1/en
Publication of WO2000068259A2 publication Critical patent/WO2000068259A2/en
Publication of WO2000068259A3 publication Critical patent/WO2000068259A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Use of a polypeptide which comprises (a) the sequence of SEQ ID No. 2, (b) a variant of (a) which is capable of generating a protective immune response to S. pyogenes, or (c) a fragment of (a) or (b) of at least 6 amino acids in length which is capable of generating a protective immune response to S. pyogenes, in the manufacture of medicament for use as a vaccine against S. pyogenes. A pharmaceutical composition for use in vaccinating against S. pyogenes or Group B streptococcus comprises a polypeptide which comprises: (A) the amino acid sequence of SEQ ID No 2, (B) a variant of (A) which is capable of conferring protective immunity to S. pyogenes or Group B streptococcus, or (C) a fragment of (A) or (B) of at least 6 amino acids in length which is capable of conferring protective immunity to S. pyogenes or Group B streptococcus.
PCT/IB2000/000726 1999-05-05 2000-05-05 Vaccine Ceased WO2000068259A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE60022995T DE60022995T2 (en) 1999-05-05 2000-05-05 VACCINE
CA002372497A CA2372497A1 (en) 1999-05-05 2000-05-05 Vaccine composition comprising r28 protein of streptococcus pyogenes
EP00927666A EP1175437B1 (en) 1999-05-05 2000-05-05 Vaccine
AT00927666T ATE305941T1 (en) 1999-05-05 2000-05-05 VACCINE
AU46051/00A AU778526B2 (en) 1999-05-05 2000-05-05 Vaccine composition
US09/959,594 US7220415B1 (en) 1999-05-05 2000-05-05 Vaccine composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9910375.6 1999-05-05
GBGB9910375.6A GB9910375D0 (en) 1999-05-05 1999-05-05 Vaccine composition

Publications (2)

Publication Number Publication Date
WO2000068259A2 WO2000068259A2 (en) 2000-11-16
WO2000068259A3 true WO2000068259A3 (en) 2001-07-12

Family

ID=10852842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/000726 Ceased WO2000068259A2 (en) 1999-05-05 2000-05-05 Vaccine

Country Status (9)

Country Link
US (1) US7220415B1 (en)
EP (1) EP1175437B1 (en)
AT (1) ATE305941T1 (en)
AU (1) AU778526B2 (en)
CA (1) CA2372497A1 (en)
DE (1) DE60022995T2 (en)
ES (1) ES2250131T3 (en)
GB (1) GB9910375D0 (en)
WO (1) WO2000068259A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082327A2 (en) * 2002-03-28 2003-10-09 Brenntag Biosector A/S Combined dna/protein vaccine compositions
WO2004018646A2 (en) * 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010317A2 (en) * 1992-11-02 1994-05-11 The General Hospital Corporation Conjugate vaccine against group b streptococcus
WO1998006428A1 (en) * 1996-08-16 1998-02-19 The Uab Research Foundation Mucosal immunogens for novel vaccines
EP0866133A2 (en) * 1997-03-19 1998-09-23 Brigham And Women's Hospital, Inc. A group b streptococcus vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE459503B (en) 1985-05-03 1989-07-10 Excorim Kommanditbolag HYBRID DNA MOLECULE CONTAINING DNA SEQUENCE CODING FOR PROTEIN G AND PROCEDURE FOR PRODUCING PROTEIN G
JPH03503117A (en) 1988-02-12 1991-07-18 ハイテク　レセプター　アーベー Immunoglobulin-binding substances, their subfragments, their production methods, reagent kits, and immunoglobulin-binding substances
EP0367890A1 (en) 1988-11-11 1990-05-16 HighTech Receptor AB Protein Arp, with immunoglobulin A binding activity, cloning and expression thereof
PT656014E (en) 1993-03-19 2003-09-30 Gunnar Lindahl PROTEIN RIB, A CELL SURFACE PROTEIN CONFESSING IMMUNITY TO MANY STREPTOPES OF GROUP B ESTREPTOCOCKS: PROCESS FOR PURIFICATION OF PROTEIN, REAGENT CASE AND PHARMACEUTICAL COMPOSITION
US6015889A (en) * 1993-03-19 2000-01-18 Gunnar Lindahl Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010317A2 (en) * 1992-11-02 1994-05-11 The General Hospital Corporation Conjugate vaccine against group b streptococcus
WO1998006428A1 (en) * 1996-08-16 1998-02-19 The Uab Research Foundation Mucosal immunogens for novel vaccines
EP0866133A2 (en) * 1997-03-19 1998-09-23 Brigham And Women's Hospital, Inc. A group b streptococcus vaccine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
J D CHAPPELL ET AL: "Demonstration of protection in mice from a lethal challenge of three M serotypes of Streptococcus pyogenes using an M-negative vaccine", VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 11, 1993, pages 643 - 649, XP002137199, ISSN: 0264-410X *
LACHENAUER C S ET AL: "Mosaicism in the alpha-like protein genes of group B streptococci.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 17, 15 August 2000 (2000-08-15), August 15, 2000, pages 9630 - 9635, XP002152238, ISSN: 0027-8424 *
STAALHAMMAR-CARLEMALM MARGARETHA ET AL: "Cross-protection between group A and group B streptococci due to cross-reacting surface proteins.", JOURNAL OF INFECTIOUS DISEASES, vol. 182, no. 1, July 2000 (2000-07-01), pages 142 - 149, XP002156997, ISSN: 0022-1899 *
STAALHAMMAR-CARLEMALM MARGARETHA ET AL: "The R28 protein of Streptococcus pyogenes is related to several group B streptococcal surface proteins, confers protective immunity and promotes binding to human epithelial cells.", MOLECULAR MICROBIOLOGY, vol. 33, no. 1, July 1999 (1999-07-01), pages 208 - 219, XP000964694, ISSN: 0950-382X *
WÄSTFELT MARIA ET AL: "Identification of a family of streptococcal surface proteins with extremely repetitive structure.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 31, 1996, pages 18892 - 18897, XP002152237, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU4605100A (en) 2000-11-21
ES2250131T3 (en) 2006-04-16
WO2000068259A2 (en) 2000-11-16
DE60022995T2 (en) 2006-06-22
EP1175437B1 (en) 2005-10-05
EP1175437A2 (en) 2002-01-30
AU778526B2 (en) 2004-12-09
GB9910375D0 (en) 1999-06-30
CA2372497A1 (en) 2000-11-16
US7220415B1 (en) 2007-05-22
ATE305941T1 (en) 2005-10-15
DE60022995D1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
CA2230885A1 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
EP2011510A3 (en) Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
JP2002542827A5 (en)
CA2123579A1 (en) Recombinant multivalent m protein vaccine
CA2395499A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
JP2003500040A5 (en)
EP1731166A3 (en) Streptococcus pneumoniae proteins and vaccines
WO2000053767A3 (en) Nucleic acid respiratory syncytial virus vaccines
CA2014033A1 (en) Compositions and treatments for pneumonia in animals
JP2002533125A5 (en)
BR9812240A (en) Altered g protein or rsv polypeptide, use of it, nucleic acid molecule encoding an altered g protein or rsv polypeptide, nucleic acid construction, recombinant host cell, processes of producing an altered g protein or rsv polypeptide immunogenic composition , to induce an immune response in a vertebrate, to inhibit the induction of disease increase after vaccination and subsequent infection of a vertebrate with rsv and to immunize a vertebrate against rsv, vaccine composition, vaccine, and, composition immunogenic
WO2001081380A3 (en) Immunogenic pneumococcal protein and vaccine compositions thereof
EP0775746A3 (en) Coccidiosis poultry vaccine
MXPA02005506A (en) Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens.
CA2100591A1 (en) Avirulent anti-rabies vaccine
AU3172095A (en) Coccidiosis poultry vaccine
GB9910375D0 (en) Vaccine composition
NZ507983A (en) A polypeptide comprising the amino acid of an n- terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
DK1005487T3 (en) Outer 74 kD membrane protein from Moraxella catarrhalis
AU2043597A (en) Human taki dna encoding the same
AU704703B2 (en) Respiratory syncytial virus protein G expressed on bacterial membrane
WO2002013845A3 (en) Inflammation related g-protein coupled receptor
ATE312923T1 (en) MORAXELLA CATARRHALIS BASB034 POLYPEPTIDES AND USES THEREOF
CA2250433A1 (en) Human dnase ii
WO2003064446A3 (en) Plasma protein-binding peptides from bacterial curli

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 46051/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2372497

Country of ref document: CA

Ref country code: CA

Ref document number: 2372497

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000927666

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000927666

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09959594

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 46051/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000927666

Country of ref document: EP